SCHEMBL61446

SCHEMBL61446

CCCCCC[CH]CC1CCC(C(C)C)CC1

nearest known ligand 0.35

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.32
FAAH O00519 1/20 0.31
ADH1B P00325 1/20 0.30
ADH1C P00326 1/20 0.30
ADH1A P07327 1/20 0.30
ADH4 P08319 1/20 0.30
ADH7 P40394 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9213021 0.80 CYP1A2 (0.45) TSHRFAAH
SCHEMBL4167546 0.79
SCHEMBL9210732 0.78 CYP1A2 (0.48) TSHR
SCHEMBL9211184 0.78 CYP1A2 (0.48) TSHR
SCHEMBL1524844 0.77 CYP1A2 (0.46) TSHRFAAH
SCHEMBL61447 0.76 TP53 (0.45)
SCHEMBL62543 0.75 THRA (0.36) TSHRFAAH
SCHEMBL28222077 0.74 CYP1A2 (0.46)
SCHEMBL5259200 0.71 CYP1A2 (0.48) TSHR
Octanol SCHEMBL7602266 0.70 LMNA (0.46) TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 114 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230218633-A1 METHODS OF TREATING ORAL MUCOSITIS GALERA LABS, LLC 2023-07-13 US disclosed
US-11612608-B2 Methods of treating oral mucositis GALERA LABS, LLC (US) 2023-03-28 US disclosed
US-20200215077-A1 METHODS OF TREATING ORAL MUCOSITIS BIOSSIL INC. (CA) 2020-07-09 US disclosed
US-10610533-B2 Methods of treating oral mucositis GALERA LABS, LLC (US) 2020-04-07 US disclosed
EP-3527079-A1 METHODS OF TREATING ORAL MUCOSITIS Galera Labs, LLC (US) 2019-08-21 EP disclosed
EP-2056675-B1 METHODS OF TREATING ORAL MUCOSITIS GALERA LABS LLC (US) 2019-01-09 EP disclosed
US-20180333421-A1 METHODS OF TREATING ORAL MUCOSITIS BIOSSIL INC. (CA) 2018-11-22 US disclosed
EP-3287464-A1 ONE POT SYNTHESIS OF TETRAZOLE DERIVATIVES OF SIROLIMUS Abbott Laboratories (US) 2018-02-28 EP disclosed
US-9855279-B2 Methods of treating oral mucositis GALERA LABS, LLC (US) 2018-01-02 US disclosed
EP-2859916-B1 Combination of an antimitotic agent and a selective superoxide dismutase mimetic in antitumor therapy GALERA LABS LLC (US) 2017-11-29 EP disclosed
WO-1997006830-A1 METHODS OF DIAGNOSTIC IMAGE ANALYSIS USING BIOCONJUGATES OF METAL COMPLEXES OF NITROGEN-CONTAINING MACROCYCLIC LIGANDS MONSANTO COMPANY (US) 1997-02-27 WO disclosed
EP-0756495-A1 DIAGNOSTIC IMAGE ANALYSIS WITH METAL COMPLEXES MONSANTO COMPANY (US) 1997-02-05 EP disclosed
WO-1996040658-A1 PROCESS FOR PREPARING SUBSTITUTED POLYAZAMACROCYCLES MONSANTO COMPANY (US) 1996-12-19 WO disclosed
WO-1995028968-A1 DIAGNOSTIC IMAGE ANALYSIS WITH METAL COMPLEXES MONSANTO COMPANY (US) 1995-11-02 WO disclosed
EP-0679155-A1 MANGANESE COMPLEXES OF NITROGEN-CONTAINING MACROCYCLIC LIGANDS EFFECTIVE AS CATALYSTS FOR DISMUTATING SUPEROXIDE. MONSANTO CO (US) 1995-11-02 EP disclosed
EP-0421441-B1 Pantothenic acid derivatives FUJIREBIO KK (JP) 1995-01-25 EP disclosed
WO-1994015925-A1 MANGANESE COMPLEXES OF NITROGEN-CONTAINING MACROCYCLIC LIGANDS EFFECTIVE AS CATALYSTS FOR DISMUTATING SUPEROXIDE MONSANTO COMPANY (US) 1994-07-21 WO disclosed
EP-0524161-A1 Manganese complexes of nitrogen containing macrocyclic ligands effective as catalysts for dismutating superoxide MONSANTO COMPANY (US) 1993-01-20 EP disclosed
US-5120738-A Cardiovascular disorders FUJIREBIO INC. (JP) 1992-06-09 US disclosed
EP-0421441-A2 Pantothenic acid derivatives FUJIREBIO INC. (JP) 1991-04-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180333421-A1 METHODS OF TREATING ORAL MUCOSITIS LPO, SOD3, MPO TSHR 4467/4885FAAH 3604/4885ADH1B 193/4885
US-20200215077-A1 METHODS OF TREATING ORAL MUCOSITIS LPO, SOD3, MPO TSHR 4467/4885FAAH 3604/4885ADH1B 193/4885
US-20230218633-A1 METHODS OF TREATING ORAL MUCOSITIS LPO, SOD3, MPO TSHR 4467/4885FAAH 3604/4885ADH1B 193/4885
US-10610533-B2 Methods of treating oral mucositis LPO, SOD3, MPO TSHR 4467/4885FAAH 3604/4885ADH1B 193/4885
US-11612608-B2 Methods of treating oral mucositis LPO, SOD3, MPO TSHR 4467/4885FAAH 3604/4885ADH1B 193/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.